Page 19 - Demo

Journal of Rural Medicine%u4e61%u6751%u533b%u5b66%u7b2c 2 %u5377%u25c6%u7b2c 4 %u671f%u25c6%u7248%u672c 1.0 %u25c6 2025 %u5e74%u6587%u7ae0%u7c7b%u578b%uff1a%u8bba%u6587 | %u520a%u53f7%uff08ISSN%uff09%uff1a3060-947X13 Copyright %u00a9 This work is licensed under a Commons Attibution-Non Commercial 4.0 International License.Pharmacokinet, 2012, 51(5): 277-304.[32] Hanley M J, Abernethy D R, Greenblatt D J. Effect of obesityon the pharmacokinetics of drugs in humans[J]. Clin Pharmacokinet, 2010, 49(2): 71-87.[33] Wang S T, Li Y. Development of a UPLC-MS/MS methodfor routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of theirtherapeutic reference ranges for Chinese patients[J]. Biomed Chromatogr, 2017, 31(8): 201-205.[34] Sparshatt A, Taylor D, Patel M X, et al. Amisulpride - dose, plasma concentration, occupancy and response: implications fortherapeutic drug monitoring[J]. Acta Psychiatr Scand, 2009, 120(6): 416-28.[35] %u9ec4%u6587%u707f%uff0c%u9648%u91d1%u5170%uff0c%u5e84%u6dd1%u4e3d%uff0c%u7b49 . %u8499%u7279%u5361%u6d1b%u6a21%u62df%u4f18%u5316%u7cbe%u795e%u5206%u88c2%u75c7%u60a3%u8005%u6c28%u78fa%u5fc5%u5229%u7684%u7ef4%u6301%u7ed9%u836f%u65b9%u6848 [J]. %u4e2d%u56fd%u533b%u9662%u836f%u5b66%u6742%u5fd7%uff0c2024%uff0c44(6)%uff1a696-701.[36] Qu K, Zhou Q, Tian L, et al. Amisulpride steady-state plasmaconcentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data[J]. Int ClinPsychopharmacol, 2022, 37(6): 255-262.[37] Wu S, Zhu G, Zhou D, et al. Application value of UPLC-MS/MS in detecting serum concentration of anti-schizophrenic drugs inpatients with mental illnes[J]. Am J Transl Res, 2021, 13(5): 5460-5467.[38] %u738b %u5c11 %u4ead . Ultra-high performance liquid chromatography tandemmass spectrometry method for detection of anti-schizophrenic drugs andthe evaluation of their therapeutic reference ranges[J]. China MedicalAbstracts(Internal Medicine), 2017, 34(4): 194.[39] %u4e01%u9756%uff0c%u5f20%u9501%uff0c%u90a2%u6b22%uff0c%u7b49 . 6 %u79cd%u7b2c%u4e8c%u4ee3%u6297%u7cbe%u795e%u75c5%u836f%u7269%u6cbb%u7597%u836f%u7269%u76d1%u6d4b%u7ed3%u679c%u7684%u56de%u987e%u6027%u5206%u6790 [J]. %u4e2d%u56fd%u533b%u9662%u836f%u5b66%u6742%u5fd7%uff0c2024%uff0c44(1)%uff1a88-93.[40] %u5f20%u71d5%uff0c%u5b59%u4e3d%u838e%uff0c%u674e%u5a75%uff0c%u7b49 . %u6c28%u78fa%u5fc5%u5229%u6cbb%u7597%u7cbe%u795e%u5206%u88c2%u75c7%u7684%u6d53%u5ea6%u53c2%u8003%u8303%u56f4%u548c%u8b66%u6212%u503c [J]. %u56db%u5ddd%u7cbe%u795e%u536b%u751f%uff0c2022%uff0c35(1)%uff1a31-36.[41] %u9ec4%u5584%u60c5%uff0c%u5f20%u660e%uff0c%u502a%u6653%u4f73%uff0c%u7b49 . %u57fa%u4e8e%u7fa4%u4f53%u836f%u4ee3%u52a8%u529b%u5b66%u6a21%u578b%u4eff%u771f%u63a2%u7d22%u6c28%u78fa%u5fc5%u5229%u6709%u6548%u6d53%u5ea6%u8303%u56f4 [J]. %u4e2d%u56fd%u533b%u9662%u836f%u5b66%u6742%u5fd7%uff0c2023%uff0c43(1): 16-20.[42] %u7518%u6850%u8425%uff0c%u5218%u7545%uff0c%u674e%u7433%uff0c%u7b49 . %u7cbe%u795e%u5206%u88c2%u75c7%u60a3%u8005%u6c28%u78fa%u5fc5%u5229%u8840%u836f%u6d53%u5ea6%u6cbb%u7597%u53c2%u8003%u8303%u56f4%u7684%u771f%u5b9e%u4e16%u754c%u6570%u636e%u7814%u7a76 [J]. %u4e2d%u56fd%u533b%u9662%u836f%u5b66%u6742%u5fd7%uff0c2025%uff0c45(4): 427-432.[43] %u679c%u4f1f%uff0c%u5f20%u73b2%uff0c%u738b%u521a . %u4e2d%u56fd%u7cbe%u795e%u79d1%u6cbb%u7597%u836f%u7269%u76d1%u6d4b%u4e34%u5e8a%u5e94%u7528%u4e13%u5bb6%u5171%u8bc6%uff082022 %u5e74%u7248%uff09[J]. %u795e%u7ecf%u75be%u75c5%u4e0e%u7cbe%u795e%u536b%u751f%uff0c2022%uff0c22(8)%uff1a601-608.%u3010%u4f5c%u8005%u7b80%u4ecb%u3011%u7530%u79d8%uff0c%u5973%uff0c%u897f%u5b89%u5e02%u7cbe%u795e%u536b%u751f%u4e2d%u5fc3%u4f4f%u9662%u533b%u5e08%u3002%u3010%u901a%u8baf%u4f5c%u8005%u3011%u515a%u4f1f%uff0c%u7537%uff0c%u897f%u5b89%u7cbe%u795e%u536b%u751f%u4e2d%u5fc3%u8001%u5e74%u533b%u5b66%u79d1%u4e3b%u4efb%u533b%u5e08%u3002